Protocol Number: ACE-LY-002

Protocol Title: An Open-label, Phase 1b Study of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Version: 2.0

Version date: 20 March 2018

The undersigned have reviewed this plan and find it to be consistent with the requirements of the protocol as it applies to their respective areas

Prepared by

[Blank]
Associate Director Biostatistics

CONFIDENTIAL
This document (and all copies thereof) is the property of Acerta Pharma and contains valuable trade secrets and confidential information, including proprietary technical and business information. By accepting this document, you agree that the Confidential Information contained herein will not be disclosed to others without prior written authorization from Acerta Pharma and shall only be used for the purposes intended by the document.
Statistical Analysis Plan

An Open-label, Phase 1b Study of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Protocol Number: ACE-LY-002

Version: 2.0
Date: 20 March 2018
Study Statistician: [Redacted]
TABLE OF CONTENTS

Table of Contents............................................................................................................ 2
Table of Abbreviations..................................................................................................... 4

1. INTRODUCTION .................................................................................................... 5

2. OBJECTIVES ......................................................................................................... 5
   2.1 Primary Objective........................................................................................... 5
   2.2 Secondary Objectives .................................................................................... 5

3. STUDY OVERVIEW ............................................................................................... 5
   3.1 Study Design.................................................................................................. 5
   3.2 Sample Size................................................................................................... 6

4. STUDY ENDPOINTS .............................................................................................. 6
   4.1 Primary Endpoints.......................................................................................... 6
   4.2 Secondary Endpoints ..................................................................................... 6
   4.3 PK and PD Parameters .................................................................................. 7

5. HYPOTHESES AND MULTIPLICITY .................................................................... 7

6. ANALYSIS SETS.................................................................................................... 7
   6.1 All-treated Population..................................................................................... 7

7. INTERIM ANALYSIS AND EARLY STOPPING GUIDELINES ................................ 7

8. FINAL ANALYSIS AND CLINICAL STUDY REPORT ............................................. 7

9. MISSING VALUES................................................................................................. 7
   9.1 Missing Safety Data....................................................................................... 8
   9.2 Missing Efficacy Data..................................................................................... 8

10. STATISTICAL METHODS OF ANALYSIS............................................................. 8
    10.1 General Principles.......................................................................................... 8
    10.2 Subject Accountability................................................................................... 8
    10.3 Important Protocol Deviations ...................................................................... 9
    10.4 Baseline Data................................................................................................ 9
        10.4.1 Demographics........................................................................................ 9
        10.4.2 Baseline Characteristics........................................................................ 9
        10.4.3 Baseline Disease Characteristics.......................................................... 9
    10.5 Treatment and Medications.......................................................................... 10
        10.5.1 Prior Anticancer Therapies................................................................... 10
        10.5.2 Prior and Concomitant Medications..................................................... 10
10.5.3 Exposure to Study Drug .................................................................11
10.6 Analyses of Safety Endpoints ..............................................................11
  10.6.1 Treatment-Emergent Adverse Events (TEAEs) .........................11
  10.6.2 Adverse Events of Clinical Interest ...........................................12
  10.6.3 Laboratory Test Results ...............................................................12
  10.6.4 Vital Signs ..................................................................................12
  10.6.5 ECOG Performance Score ..........................................................13
  10.6.6 Electrocardiogram .................................................................13
10.7 Analyses of Efficacy Endpoints ..........................................................13
  10.7.1 Definitions ................................................................................13
  10.7.2 Analysis Methods .........................................................................14

11. CHANGE FROM PROTOCOL-SPECIFIED ANALYSES .........................14

12. LITERATURE CITATIONS / REFERENCES ..............................................14

13. APPENDIX ..............................................................................................16
  13.1 Definitions ......................................................................................16
    13.1.1 Study Day ................................................................................16
    13.1.2 Baseline Value and Post-baseline Value ....................................16
    13.1.3 Duration of Treatment and Time on Study ..............................16
    13.1.4 Average Daily Dose and Relative Dose Intensity .....................16
    13.1.5 Age ..........................................................................................17
    13.1.6 Year and Month .........................................................................17
    13.1.7 Treatment-emergent Adverse Events .......................................17
    13.1.8 International Prognostic Index (IPI) and Revised-IPI ...............17
    13.1.9 Extranodal Disease and Bone Marrow Involvement at Baseline ..................................................................................17
    13.1.10 Tumor Bulk at Baseline ............................................................18
  13.2 Imputation Rules for Partial or Missing Dates ..................................18
  13.3 Censoring Rules for Duration of Response ....................................20
  13.4 Censoring Rules for Progression-Free Survival .............................21
  13.5 Censoring Rules for Time-to-Next Treatment ..................................22
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC</td>
<td>activated B-cell</td>
</tr>
<tr>
<td>AE(s)</td>
<td>adverse event(s)</td>
</tr>
<tr>
<td>BID</td>
<td>twice per day</td>
</tr>
<tr>
<td>BTK</td>
<td>Bruton's tyrosine kinase</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CR</td>
<td>complete response</td>
</tr>
<tr>
<td>CSR</td>
<td>clinical study report</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>DLBCL</td>
<td>diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>DOR</td>
<td>duration of response</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>IPD</td>
<td>important protocol deviation</td>
</tr>
<tr>
<td>IPI</td>
<td>International prognostic index</td>
</tr>
<tr>
<td>LHD</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>NK</td>
<td>natural killer</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>ORR</td>
<td>overall response rate</td>
</tr>
<tr>
<td>PD</td>
<td>progressive disease</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PR</td>
<td>partial response</td>
</tr>
<tr>
<td>PT</td>
<td>preferred term</td>
</tr>
<tr>
<td>R-IPI</td>
<td>revised international prognostic index</td>
</tr>
<tr>
<td>R/R</td>
<td>relapsed or refractory</td>
</tr>
<tr>
<td>SAE(s)</td>
<td>serious adverse event(s)</td>
</tr>
<tr>
<td>SAP</td>
<td>statistical analysis plan</td>
</tr>
<tr>
<td>SD</td>
<td>stable disease</td>
</tr>
<tr>
<td>SD</td>
<td>standard deviation</td>
</tr>
<tr>
<td>SOC</td>
<td>system organ class</td>
</tr>
<tr>
<td>TEAE(s)</td>
<td>treatment-emergent adverse events</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
1. **INTRODUCTION**

The purpose of this statistical analysis plan (SAP) is to provide details of efficacy and safety analyses that have been outlined within protocol amendment 3 for study ACE-LY-002, entitled “An Open-label, Phase 1b Study of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma” dated January 13, 2016. The original SAP based on same protocol was for interim safety clinical study report (CSR) to support the new drug application (NDA). This SAP is updated to include efficacy analysis. Any changes to the methods described in the final SAP will be documented in the clinical study report (CSR).

Separate reports will be generated for pharmacokinetics (PK) and pharmacodynamics (PD) data.

Hereafter, acalabrutinib (a generic name for ACP-196) will be used in place of ACP-196 in this document.

The analysis will be executed by the biometrics department of Acerta Pharma unless otherwise specified.

2. **OBJECTIVES**

2.1 **Primary Objective**

- To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory (R/R) ABC subtype of diffuse large B-cell lymphoma (DLBCL).

2.2 **Secondary Objectives**

- To characterize the PK profile of acalabrutinib.
- To evaluate the PD effects of acalabrutinib.
- To evaluate the activity of acalabrutinib as measured by response rate, duration of response (DOR), time-to-next treatment, and progression-free survival (PFS).

3. **STUDY OVERVIEW**

3.1 **Study Design**

This study is a multicenter and open-label study. Twenty subjects, 10 relapsed and 10 refractory, will be enrolled and will take 100 mg of acalabrutinib twice per day (BID). Relapsed subjects will be defined as subjects who have had a partial response (PR) or
better (Cheson 2014 or Cheson 2007 criteria) from the previous anticancer therapy and have now progressed. Refractory subjects will be defined as subjects whose best response to the previous anticancer therapy was stable disease (SD) or who did not respond to therapy.

Treatment with acalabrutinib may be continued until disease progression or an unacceptable drug-related toxicity occurs. Tumor assessments will be performed at 8- to 12-week intervals during the trial. All subjects who discontinue study drug will have a safety follow-up visit 30 (±7) days after the last dose of study drug unless they have started another cancer therapy within that timeframe.

All subjects will have hematology, chemistry, and urinalysis safety panels done at screening. Once dosing commences (Day 1), all subjects will be evaluated for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, every 2 weeks in Cycle 2 and monthly thereafter. PK and PD testing will be done in Cycle 1 and Cycle 2. Subjects showing clinical benefit and who are tolerating acalabrutinib may remain on study through the end of Cycle 12. The end of trial is defined as the point when the last subject enrolled completes the end of Cycle 12 or withdraws for any reason and completes the 30-day follow-up visit (if applicable), whichever occurs first.

### 3.2 Sample Size

The trial design is specified because of its practical simplicity and use of a biomarker, rather than power considerations. The sample size of 20 subjects in a Phase 1b study is considered adequate to evaluate the initial safety, PK/PD, and activity of acalabrutinib in this patient population.

### 4. STUDY ENDPOINTS

#### 4.1 Primary Endpoints

Primary endpoints are:

- Frequency and severity of AEs/SAEs.
- Frequency of AEs requiring discontinuation, dose delay or dose modification of study drug.

#### 4.2 Secondary Endpoints

Secondary efficacy endpoints are:
• Overall response rate (ORR) per Lugano criteria as assessed by investigator;
• DOR per Lugano criteria as assessed by investigator;
• PFS per Lugano criteria as assessed by investigator;
• Time-to-next treatment per Lugano criteria as assessed by investigator.

Secondary PK/PD endpoints are:
• Plasma PK of acalabrutinib;
• Occupancy of BTK by acalabrutinib in peripheral blood mononuclear cells;
• The effect of acalabrutinib on biologic markers of B-cell function.

4.3 PK and PD Parameters
Refer to separate reports for PK and PD parameters.

5. HYPOTHESES AND MULTIPLICITY

No formal statistical hypotheses will be tested. The clinical hypotheses are that acalabrutinib monotherapy is safety and effective in subjects with R/R DLBCL.

6. ANALYSIS SETS

6.1 All-treated Population
All-treated population is defined as all enrolled subjects who receive ≥ 1 dose of study drug. All-treated population will be used for evaluating the safety and efficacy unless otherwise specified.

7. INTERIM ANALYSIS AND EARLY STOPPING GUIDELINES
No formal interim analysis will be conducted.

8. FINAL ANALYSIS AND CLINICAL STUDY REPORT
The final analysis of primary and secondary efficacy endpoint will occur at the end of trial. The end of trial is defined as when last patient enrolled completes the end of Cycle 12, or withdraws for any reason and completes the 30-day follow-up visit, whichever occurs first. The CSR will be written based on the final analysis.

9. MISSING VALUES
9.1 Missing Safety Data

Conservative imputation rules will be applied in handling partial or missing dates for AE onset and stop dates, start and end dates of concomitant medication, start date of subsequent anticancer therapy, date of initial diagnosis and death date. If dates are completely missing, no imputation will be made. The details of imputation algorithm for dates are included in Appendix 13.2.

Missing safety data other than partial dates will not be imputed.

9.2 Missing Efficacy Data

The method of handing missing data and censoring data is described in the definition for each of the efficacy endpoints, mentioned at section 13.3, 13.4 and 13.5.

10. STATISTICAL METHODS OF ANALYSIS

10.1 General Principles

Descriptive statistics will be used to summarize disposition, demographics, baseline characteristics, disease characteristics, prior anticancer therapy, concomitant medication, study drug administration, efficacy and safety outcomes. Descriptive summary of discrete data will be present the sample size and incidence as frequency and percentage. Descriptive summaries of continuous data will be present the sample size, group mean, standard deviation, median, and range.

Confidence intervals (CIs), when presented, will generally be constructed at the 95% level. For binomial variables, the exact method for CIs will be employed unless otherwise specified.

Calculation of time to event or duration of event (e.g., DOR) will be based on actual study day of event rather than nominal visit date.

10.2 Subject Accountability

The number of subjects enrolled by site, country will be presented. Subject disposition will be summarized for all enrolled subjects including the following information:

- Subject status on study drug
- Count and reason for study drug discontinuation
10.3 **Important Protocol Deviations**

Important Protocol Deviations (IPDs) categories are defined and managed by the study team during the IPD reviews throughout the study before database lock. These definitions of IPD categories, sub-category codes, and descriptions will be used during the study. The final IPD list is used to produce the summary of IPDs table and the List of IPDs.

10.4 **Baseline Data**

10.4.1 **Demographics**

- Age (year, continuous)
- Age category (<65 vs. ≥65 years; <= 60 vs. >60 years)
- Gender
- Ethnicity
- Race
- Region (United States, United Kingdom)

10.4.2 **Baseline Characteristics**

- Eastern Cooperative Oncology Group (ECOG) performance score
- Height (cm, continuous)
- Weight (kg, continuous)

10.4.3 **Baseline Disease Characteristics**

- Time from initial diagnosis to the first dose of study drug (months, continuous)
- Baseline B symptoms (weight loss, fever, night sweats) (yes, no)
- Number of prior therapy regimens (1-2 vs. >=3 regimens; continuous)
- Autologous stem cell transplant (yes)
- Tumor bulk (<5 cm vs. ≥5 cm)
• Bulky disease defined as tumor bulk ≥10 cm (yes, no)
• Ann Arbor stage for lymphoma (stage I, II, III, IV; stage 1-II vs. III-IV)
• Bone marrow involvement (yes, no)
• Extranodal disease (yes, no)
• Number of extranodal sites (0-1 vs. >=2)
• Serum lactate dehydrogenase (LHD) (normal, above normal)
• Baseline QTcF (mean, SD, median, min, max)
• International Prognostic Index (IPI) (low, low-intermediate, high-intermediate, high)
• Revised IPI (R-IPI) (very good, good, poor)

10.5 Treatment and Medications

10.5.1 Prior Anticancer Therapies

A prior anticancer therapy is defined as a systemic therapy received by subjects, either as a single or combination therapy, for the treatment of DLBCL with a start or end date earlier than the date of first dose of study drug. Therapies given as a consolidation or for maintenance of a response or remission will not be considered as a separate regimen. Preparatory regimen and transplant will not be considered as separate regimens. Prior number of regimens for DLBCL is the total number of lines of therapy that a subject received for DLBCL before he/she entered this study. The number of lines and type of prior therapy for DLBCL will be summarized.

10.5.2 Prior and Concomitant Medications

Data reported on concomitant medications CRF will be used. Medications started or ended prior to the first dose of study drug will be considered as prior treatment. Concomitant medications are defined as all medications used on or after the first dose of study drug, through the treatment phase, and through 30 days following the last dose of study drug. Using this definition, a medication can be classified as both prior and concomitant medication. The start date and end date will be imputed based on the rules provided in Appendix 13.2. Medications with completely missing start and stop dates will be considered as both prior and concomitant medications.
Except for antineoplastic agents or other systemic therapies for DLBCL after enrollment, prior and concomitant medications will be summarized by the World Health Organization (WHO) Drug Dictionary therapeutic class and preferred term.

10.5.3 Exposure to Study Drug

Descriptive statistics (n, mean, standard deviation, median, minimum and maximum) will be used to summarize:

- Duration of exposure (the interval (months) between first dose date and last dose date);
- Actual cumulative dose administered (the total dose administered during the drug exposure period);
- Average daily dose (the ratio of actual cumulative dose administered and duration of exposure);
- Relative dose intensities (the ratio of actual cumulative dose to the planned cumulative dose through the drug exposure period).

Dose withholding and dose deduction by dose change reasons will be summarized and presented as the number and percentage of subjects with non-missing data per category. Dose withholding is defined as missing doses for ≥ 7 consecutive days. Dose reduction is defined as taking lower dose level (100 mg per day) for ≥ 3 consecutive days.

10.6 Analyses of Safety Endpoints

10.6.1 Treatment-Emergent Adverse Events (TEAEs)

The Medical Dictionary for Regulatory Activities (MedDRA) will be used to code all AEs to a system organ class (SOC) and a preferred term (PT). The severity of AEs will be assessed and graded by the investigator by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 or higher. Treatment related AEs are events assessed by investigator as related to study drug.

Treatment-emergent AEs will be summarized by SOC and PT, and by CTCAE toxicity grade. The drug-related AEs, serious adverse events (SAEs) and drug-related SAEs, AEs leading to treatment discontinuation, drug dose delay and dose modification will be summarized by PT and by CTCAE toxicity grade.
Death information is reported in the study exit CRF for all deaths. Incidences of deaths are to be reported, along with the primary cause of death. A summary table and a listing will be provided for death.

10.6.2 Adverse Events of Clinical Interest

Adverse events of clinical interest (ECI) corresponding search strategy are defined in section 8.5.1 of the SAP for acalabrutinib integrated summary of safety dated 21 March 2017.

Subject incidence of ECI will be summarized using the CTCAE Version 4.03 or higher.

10.6.3 Laboratory Test Results

Laboratory data for hematology, serum chemistry, serum immunoglobulin, and T/B/natural killer (NK) cell counts to 30 days after last dose of study drug or up to the safety follow-up visit date, whichever is later, will be summarized. Applicable laboratory test results will be graded according to CTCAE Version 4.03 or higher. Generic normal ranges specified in American Medical Association (AMA) Manual of Style 10th Edition (2017) will be applied whenever reference ranges are not available.

Shift from baseline to worst grade during the treatment will be provided as shift tables for selected parameters. Figures of selected parameter will be plotted overtime as appropriate.

All-treated subjects with at least one post-baseline lab test result will be included in the tables.

10.6.4 Vital Signs

Vital signs include systolic blood pressure, diastolic blood pressure, pulse rate, body temperature and respiratory rate. Summary statistics (mean, standard deviation, median, minimum and maximum) will be produced for vital signs at baseline, post-baseline values from the last visit, minimum and maximum post-baseline values, and changes of these post-baseline values from baseline.

All-treated subjects with at least one post-baseline lab test result will be included in the tables.
10.6.5 **ECOG Performance Score**

Shift of ECOG score from baseline to worst post-baseline score during the treatment will be provided as a shift table.

10.6.6 **Electrocardiogram**

ECG data is collected at screening. The investigator assessment of clinical significance categorized as normal, abnormal but not clinically significant, and abnormal clinically significant, will be summarized. The number of subjects with corrected QT interval (QTc) greater than 480 msec will also be provided. A listing of subjects with abnormal and clinically significant baseline ECG results or QTc> 480 msec will be produced.

10.7 **Analyses of Efficacy Endpoints**

10.7.1 **Definitions**

- **Overall Response Rate (ORR)**

  ORR is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) per Lugano criteria as assessed by investigator.

- **Duration of Response (DOR)**

  DOR is defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of definitive DLBCL disease progression or death from any cause. Subjects not meeting the criteria and alive by the analysis data cutoff date will be censored and the detail censoring rules for DOR are summarized in Appendix 13.3.

- **Progression-Free Survival (PFS)**

  PFS is defined as the interval from the start of acalabrutinib therapy to the earlier of the first documentation of objective DLBCL disease progression or death from any cause. Subjects not meeting the criteria and alive by the analysis data cutoff date will be censored and the detail censoring rules for primary and sensitivity analyses of PFS are summarized Appendix 13.4.

- **Time-to-Next Treatment**

  Time-to-next treatment is defined as the time from start of acalabrutinib therapy for DLBCL to the start of the next treatment for DLBCL. Data from subjects who have not received subsequent therapy for DLBCL by the analysis data cutoff date will be
censored and the detail of censoring rules for time-to-next treatment are summarized in Appendix 13.5.

10.7.2 **Analysis Methods**

Efficacy analyses will be performed on the R/R cohorts and total. The analysis of ORR, PFS, time-to-next treatment will be conducted on the all-treated population. The analysis of DOR will be conducted on the subset of the all-treated population who achieve CR or PR as the best overall response.

ORR and the corresponding 95% two-sided CI will be calculated using exact binomial distribution. Descriptive statistics will be provided for best overall response. The order of overall response category is: CR > PR > SD > PD. The number and proportion of subjects within each category of overall response as well as the associated 95% CIs will be presented.

The analysis of DOR, PFS, and time-to-next-treatment will be estimated using the Kaplan-Meier (KM) method. KM estimates with 95% CIs will be calculated for event time quartiles, and event-free rates will be calculated at selected timepoints. Given the small sample size, listings for DOR, PFS, and time-to-next treatment will be provided in lieu of summary statistics as appropriate, including the reason for censoring.

11. **CHANGE FROM PROTOCOL-SPECIFIED ANALYSES**

There is no major change from protocol-specified analyses for safety.

12. **LITERATURE CITATIONS / REFERENCES**


Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, USDHHS, NIH, NCI; publish date May 28, 2009 (v4.03: June 14, 2010).


13. APPENDIX

13.1 Definitions

13.1.1 Study Day

The study day will be calculated refer to the date of first dose of study drug. Study day 1 is defined as the date of first dose of acalabrutinib. For assessments that occur on or after first dose date, study day is defined as (date of assessment – date of first dose + 1). For assessments that occur prior to first dose date, study day is defined as (date of assessment – date of first dose).

13.1.2 Baseline Value and Post-baseline Value

Unless otherwise specified, the baseline value is defined as the last measurement taken on or prior to the first dose of study drug.

\[
\text{Change from baseline} = \text{Postbaseline Value} - \text{Baseline Value}
\]

\[
\text{Percentage change from baseline} = \left(\frac{\text{Change from baseline}}{\text{Baseline}}\right) \times 100\%
\]

13.1.3 Duration of Treatment and Time on Study

Duration of treatment will be calculated from the date of the first dose of study drug to the date of the last dose of study drug:

\[
\text{Duration of treatment} = (\text{last study drug date} - \text{frist study drug date}) + 1
\]

Time on study will be calculated from the date of the first dose of study drug to the date of study exit or analysis data cut-off date, whichever is the earliest.

\[
\text{Time on study} = (\text{study exit date or data cut date} - \text{first study medication date}) + 1
\]

13.1.4 Average Daily Dose and Relative Dose Intensity

Average daily dose (mg per day) = \[
\frac{\text{Total cumulative dose taken (mg)}}{\text{Duration of treatment}}
\]

and

Relative dose intensity = \[
\left(\frac{\text{Total cumulative dose taken}}{\text{Total expected dose}}\right) \times 100\%
\]
Total cumulative dose taken = sum of actual daily dose taken through the duration of treatment;

Total expected dose = duration of treatment \times protocol assigned daily dose

13.1.5  Age

Age in years will be calculated at the date of enrollment.

13.1.6  Year and Month

One year equals to 365.25 days and 1 month equals to 30.4375 days.

13.1.7  Treatment-emergent Adverse Events

Treatment-emergent AEs are defined as those events with onset date (actual or imputed onset date) on or after the date of first dose of acalabrutinib, through the treatment phase to last dose of acalabrutinib, and within 30 days following the last dose of acalabrutinib.

13.1.8  International Prognostic Index (IPI) and Revised-IPI

The IPI will be derived based on baseline value of 5 prognostic risk: age greater than 60 years; stage III or IV disease; elevated serum LDH; ECOG performance status of 2, 3, or 4; more than 1 extranodal site. One point is assigned for each of the above risk. The sum of the points allotted correlates with the following risk groups: low risk (0-1 points); low-intermediate risk (2 points); high-intermediate risk (3 points); high risk (4-5 points).

The R-IPI is defined based on IPI as: very good (0 points); good (1, 2 points); poor (3,4,5 points).

13.1.9  Extranodal Disease and Bone Marrow Involvement at Baseline

The data of extranodal sites of lymphoma is reported on Disease History CRF. Subjects with any sites/extra nodal notations box checked other than 'None', 'Spleen' will be considered as having extranodal disease at baseline.

Data reported on ‘Bone Marrow Biopsy and Aspirate’ CRF will be used to derive bone marrow involvement. Subjects with bone marrow biopsy and aspirate result box checked ‘Not Involved’ at baseline based on any method of assessment will be considered to have no bone marrow involved at baseline. Subjects with result box
checked ‘involved’, ‘indeterminant’ or ‘other’ will be considered to have bone marrow involvement as a conservative approach.

13.1.10 Tumor Bulk at Baseline

Data reported on Lymph Node Assessment CRF will be used to derive tumor bulk. Tumor bulk is defined as the largest diameter of a lymph node by CT scan. Bulky disease is defined as tumor bulk equal to or greater than 10.0 cm.

13.2 Imputation Rules for Partial or Missing Dates

Imputation of partial dates will be made for AE onset and stop dates, start and end dates of prior and concomitant medication, start date of subsequent anticancer therapy, date of initial diagnosis and death date. If dates are completely missing, no imputation will be made. For any partial date with missing year, no imputation will be made.

The general rule for imputation is:

- If only day is missing, then the 15th of the month will be used.
- If only year is present, then June 30th will be used.

If such imputation date for initial diagnosis is on or after date of first dose, the date of first dose – 1 will be used. If such imputed date for subsequent anticancer therapies is before date of last dose, the date of last dose + 1 will be used.

If the imputed date is for an AE start date and is in the same year and month as the first dose date but before the first dose date, the first dose date will be used, or if the imputed AE start date is after the AE end date, the AE end date will be used. If the imputed date is for an AE start date and is in the same year and month as but after the last dose date + 30 days, the last dose date + 30 days will be used.

If the imputed date is for an AE end date and is after the death date, the date of death will be used, or if the imputed AE end date is before the AE start date, the AE start date will be used.

If death year and month are available but day is missing:

- If mmyyyy for last contact date = mmyyyy for death date, set death date to the day after the last contact date.
- If mmyyyy for last contact date < mmyyyy for death date, set death date to the first day of the death month.
• If mm/yyyy for last contact date > mm/yyyy for death date, data error and do not impute.

If both month and day are missing for death date or a death date is totally missing, no imputation is made.
### 13.3 Censoring Rules for Duration of Response

<table>
<thead>
<tr>
<th>Situation</th>
<th>Outcome</th>
<th>Event Description or Censoring Reason</th>
<th>Last Analysis Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented disease progression before initiation of new anticancer therapy or on/before data cutoff date, whichever occurred first, also no more than 1 missing tumor assessments before documented disease progression</td>
<td>Event</td>
<td>Progressive Disease</td>
<td>Earliest date of documented disease progression</td>
</tr>
<tr>
<td>Death before initiation of new anticancer therapy or on/before data cutoff date, whichever occurred first, and no documented disease progression with &gt;=2 consecutive missing tumor assessment before death, also no more than 1 missing tumor assessments before death</td>
<td>Event</td>
<td>Death</td>
<td>Date of Death</td>
</tr>
<tr>
<td>New anticancer therapy Initiated before data cutoff date and before documented disease progression or death</td>
<td>Censored</td>
<td>New anti-cancer therapy</td>
<td>Date of last adequate tumor assessment on or prior to initiation of new anticancer therapy</td>
</tr>
<tr>
<td>New anti-cancer therapy before data cutoff date for subjects without documented disease progression or death</td>
<td>Censored</td>
<td>New anti-cancer therapy</td>
<td>Date of last adequate tumor assessment on or prior to initiation of new anticancer therapy</td>
</tr>
<tr>
<td>No documented disease progression, initiation of new anticancer therapy or death on/before data cutoff date</td>
<td>Censored</td>
<td>Data cutoff</td>
<td>Date of last adequate tumor assessment on or before data cutoff date</td>
</tr>
<tr>
<td>Documented disease progression or death after ≥ 2 consecutive missing tumor assessments</td>
<td>Censored</td>
<td>Consecutive missing tumor assessments</td>
<td>Date of last tumor assessment prior to the missing assessments that demonstrate lack of disease progression</td>
</tr>
<tr>
<td>No post-baseline adequate disease assessments</td>
<td>Censored</td>
<td>No post-baseline adequate disease assessments</td>
<td>Date of first dose of study drug</td>
</tr>
<tr>
<td>No baseline disease assessments</td>
<td>Censored</td>
<td>No baseline disease assessment</td>
<td>Date of first dose of study drug</td>
</tr>
</tbody>
</table>
### 13.4 Censoring Rules for Progression-Free Survival

<table>
<thead>
<tr>
<th>Situation</th>
<th>Outcome</th>
<th>Event Description or Censoring Reason</th>
<th>Last Analysis Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented disease progression before initiation of new anticancer therapy or on/before data cutoff date, whichever occurred first, also no more than 1 missing tumor assessments before documented disease progression</td>
<td>Event</td>
<td>Progressive Disease</td>
<td>Earliest date of documented disease progression</td>
</tr>
<tr>
<td>Death before initiation of new anticancer therapy or on/before data cutoff date, whichever occurred first, and no documented disease progression with &gt;=2 consecutive missing tumor assessment before death, also no more than 1 missing tumor assessments before death</td>
<td>Event</td>
<td>Death</td>
<td>Date of Death</td>
</tr>
<tr>
<td>New anticancer therapy Initiated before data cutoff date and before documented disease progression or death</td>
<td>Censored</td>
<td>New anti-cancer therapy</td>
<td>Date of last adequate tumor assessment on or prior to initiation of new anticancer therapy</td>
</tr>
<tr>
<td>New anti-cancer therapy before data cutoff date for subjects without documented disease progression or death</td>
<td>Censored</td>
<td>New anti-cancer therapy</td>
<td>Date of last adequate tumor assessment on or prior to initiation of new anticancer therapy</td>
</tr>
<tr>
<td>No documented disease progression, initiation of new anticancer therapy or death on/before data cutoff date</td>
<td>Censored</td>
<td>Data cutoff</td>
<td>Date of last adequate tumor assessment on or before data cutoff date</td>
</tr>
<tr>
<td>Documented disease progression or death after ≥ 2 consecutive missing tumor assessments</td>
<td>Censored</td>
<td>Consecutive missing tumor assessments</td>
<td>Date of last tumor assessment prior to the missing assessments that demonstrate lack of disease progression</td>
</tr>
<tr>
<td>No post-baseline adequate disease assessments</td>
<td>Censored</td>
<td>No post-baseline adequate disease assessments</td>
<td>Date of first dose of study drug</td>
</tr>
<tr>
<td>No baseline disease assessments</td>
<td>Censored</td>
<td>No baseline disease assessment</td>
<td>Date of first dose of study drug</td>
</tr>
</tbody>
</table>
### 13.5 Censoring Rules for Time-to-Next Treatment

<table>
<thead>
<tr>
<th>Situation</th>
<th>Outcome</th>
<th>Event Description or Censoring Reason</th>
<th>Last Analysis Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New anticancer therapy on or before data cutoff date</td>
<td>Event</td>
<td>new anticancer therapy</td>
<td>Initiation of new anticancer therapy</td>
</tr>
<tr>
<td>New anticancer therapy after data cutoff date</td>
<td>Censored</td>
<td>new anticancer therapy prior to cutoff date</td>
<td>Date cutoff date</td>
</tr>
<tr>
<td>No new anti-cancer therapy</td>
<td>Censored</td>
<td>No next treatment</td>
<td>last time prior to the missing assessments that demonstrate lack of DLBCL progression</td>
</tr>
</tbody>
</table>
Protocol Number: ACE-LY-002

Protocol Title: An Open-label, Phase 1b Study of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Version: 2.0

Version date: 20 March 2018

The undersigned have reviewed this plan and find it to be consistent with the requirements of the protocol as it applies to their respective areas

Prepared by

[Name]
Associate Director Biostatistics

CONFIDENTIAL
This document (and all copies thereof) is the property of Acerta Pharma and contains valuable trade secrets and confidential information, including proprietary technical and business information. By accepting this document, you agree that the Confidential Information contained herein will not be disclosed to others without prior written authorization from Acerta Pharma and shall only be used for the purposes intended by the document.